| Autor: |
Noverati, Nicholas, Yan, Vivian, Jun, Jay W., Halegoua-DeMarzio, Dina, Hann, Hie-Won |
| Předmět: |
|
| Zdroj: |
Livers; Sep2023, Vol. 3 Issue 3, p325-330, 6p |
| Abstrakt: |
Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from this virus. This case series presents details of functional cures in patients who received varying nucleos(t)ide therapies for an average of 15.3 years before losses of hepatitis B surface antigen and viral load were observed. It is imperative to understand that abbreviating therapy once a functional cure is achieved may be a possibility in treating patients in order to limit the associated costs and side effects of an otherwise lifelong therapy until other cure drugs are approved. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
